VEITH 2019Editor's PickInterviewsEditors Pick HomepageEditors Pick PeripheralPeripheral InterviewsLatest news PeripheralPeripheralLearning AreasEvents Combination of scaffold and drug in BTK intervention “without question” the right way forward
VEITH 2019Editors Pick AorticAortic InterviewsEditor's PickLatest news AorticAorticInterviewsLearning AreasEvents Trials needed to assess whether metformin impedes aneurysm progression in non-diabetic patients
ESMINT 2019Editor's PickInterviewsEditors Pick HomepageNeuroEditors Pick NeuroNeuro InterviewsLatest news NeuroLearning AreasEvents ESMINT 2019: “Vast majority” of people do not expect children to have strokes
Editor's PickInterviewsEditors Pick HomepageNeuroEditors Pick NeuroNeuro InterviewsLatest news NeuroLearning AreasEventsSNIS 2019 SNIS 2019: “Almost unethical” not to broaden thrombectomy inclusion criteria and treat more patients
Editor's PickInterviewsEditors Pick HomepageSpinalLearning AreasEditors Pick SpinalSpinal InterviewsIMAST 2019 IMAST 2019: Industry sponsored disc replacement trials should be treated with “caution”
Editor's PickEditors Pick HomepageInterviewsNeuroEditors Pick NeuroNeuro InterviewsLearning AreasEventsSNIS 2019 SNIS 2019: Next-generation thrombectomy will be “even more powerful”
IRPeripheralEditors Pick PeripheralPeripheral InterviewsLatest news PeripheralVEITHsymposium 2018 PCSK9 inhibitors, rivaroxaban and a diabetes drug are major milestones in PAD treatment
